ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Evaluation and monitoring of patients with HIV

Evaluation and monitoring of patients with HIV
Test Interval
HIV-related testing
HIV serology At baseline if there is no laboratory documentation of infection
CD4 cell count

At baseline

Every 3 to 6 months (may be extended to ≥12 months in clinically stable patients on ART*)
HIV viral load

At baseline

After ART initiation:
  • At 4 to 8 weeks
  • Every 4 to 8 weeks until the viral load is suppressed
  • Every 3 to 4 months thereafter (may be extended to every 6 months in patients who have suppressed viral loads for ≥1 year)
Genotypic resistance testing

At baseline

Prior to initiation of ART, if delayed (recommended in pregnant women; optional for others if performed at baseline visit)
HLA-B5701 testing If considering use of abacavir
Tropism testing If considering use of maraviroc
Assessing cardiovascular risk
Blood pressure check At baseline and annually (or more frequently as indicated)
Random or fasting glucose and/or hemoglobin A1c

At baseline

1 to 3 months following ART initiation or modification and then annually
Fasting lipid profile At baseline and annuallyΔ
Weight assessment At baseline and follow-up visits
Tobacco use assessment At baseline and annually
Aortic aneurysm screening (abdominal ultrasonography) Once in men 65 to 75 years old who have ever smoked
Assessing other risks
Bone densitometry

At baseline in postmenopausal women and men ≥50 years old

Subsequent testing frequency depends on findings on baseline exam
Screening for neuropsychiatric disorders
Depression screening At baseline and annually
Screening for cognitive deficits At baseline and annually
Screening for cancer
Colonoscopy

At 45 years old in asymptomatic patients at average risk

Earlier screening may be warranted for those with strong family history of colon cancer

Subsequent testing frequency depends on findings on baseline exam
Mammography Every other year or annually in women 50 to 74 years old
Cervical Pap smear (with or without HPV testing in women ≥30 years)

At baseline; interval for repeat testing depends on results and whether HPV co-testing was performed§

Additional testing may be warranted for those with abnormal results
Anal Pap smear

Consider at baseline and annually

More frequent or additional testing may be warranted for those with abnormal results
Prostate-specific antigen For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be individualized¥
Low-dose helical chest CT Adults age 50 to 80 years old who are at risk of lung cancer due to smoking (at least a 20 pack-year smoking history and are either current smokers or former smokers having quit within the past 15 years)
Screening for infections
Syphilis serology

At baseline

Annually for sexually active persons (or more frequently if at high risk)
Chlamydia and gonorrhea testing (at all sites of potential exposure)

At baseline

Annually for sexually active persons (or more frequently if at high risk)
Trichomonas

At baseline for all women

Annually for sexually active women
TB testing (TST or IGRA)

At baseline unless there is a history of a prior positive test

Annually in patients at ongoing risk for TB unless there is a history of a prior positive test
HAV and HBV serologies At baseline, with vaccination(s) in persons not immune
HCV serology, with reflex viral level for positive result

At baseline

Annually in patients at risk (eg, persons who inject drugs, men who have sex with men, transgender women)
Dilated fundoscopic exam Consider every 12 months in patients with CD4 cell count <50 cells/microL
Monitoring for medication toxicity
Complete blood count with differential

At baseline

Complete blood count with differential every 3 to 6 months when monitoring CD4 count and every year once the CD4 count is no longer monitored
BUN and creatinine‡†

At baseline

4 to 8 weeks after ART initiation and every 6 months thereafter
ALT, AST, and total bilirubin

At baseline

4 to 8 weeks after ART initiation and every 6 months thereafter
Urinalysis

At baseline

After ART initiation or change

Every 12 months on ART (every 6 months while on tenofovir disoproxil fumarate or tenofovir alafenamide-containing regimens)
This table is meant for use with UpToDate content that discusses primary care for adults with HIV. This table lists intervals for routine testing. Testing should also be performed when clinically indicated.

ALT: alanine aminotransferase; ART: antiretroviral therapy; AST: aspartate aminotransferase; BUN: blood urea nitrogen; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HLA: human leukocyte antigen; HPV: human papillomavirus; IGRA: interferon-gamma release assay; TB: tuberculosis; TST: tuberculin skin test.

* Less frequent CD4 count monitoring is appropriate in patients who have a stable CD4 cell count at a level well above the threshold for opportunistic infection risk (eg, >300 cells/microL) and have a consistently undetectable viral load. Refer to the topic that discusses patient monitoring during HIV ART for more detailed recommendations.

¶ Glycated hemoglobin should not be routinely used to diagnose diabetes mellitus in patients on ART, as HbA1c may underestimate glycemia, especially in those with a low CD4 cell count.

Δ Some experts also check lipids 1 to 3 months following ART initiation or modification.

◊ Refer to UpToDate content on breast cancer screening for more detailed information, including recommendations for other age groups.

§ Refer to the UpToDate topic on HIV and women for additional details.

¥ Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision. Refer to UpToDate content on prostate cancer screening to guide these discussions.

‡ Determination of renal function should include estimation of CrCl or glomerular filtration rate. More frequent monitoring may be indicated for patients with evidence of kidney disease (eg, proteinuria, decreased glomerular dysfunction) or increased risk of renal insufficiency (eg, patients with diabetes, hypertension).

† Some experts also suggest monitoring the phosphorus levels of patients on tenofovir disoproxil fumarate.
References:
  1. Thompson MA, Horberg MA, Agwu AL, et al. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2021; 73:e3572.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines (Accessed on March 22, 2023).
  3. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new (Accessed on March 22, 2023).
  4. Sexually Transmitted Infections Treatment Guidelines, 2021. Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7004a1-H.pdf (Accessed on March 22, 2023).
Graphic 96776 Version 12.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟